Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Pipeline Review, H2 2019’, provides in depth analysis on Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Women’s Health, Musculoskeletal Disorders and Respiratory under development targeting Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

– The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects

– The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“ARTham Therapeutics Inc

AskAt Inc

Eisai Co Ltd

Eli Lilly and Co

GlaxoSmithKline Plc

Kaken Pharmaceutical Co Ltd

Mesentech Inc

NB Health Laboratory Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Shanghai Haishi Biopharmaceutical Co Ltd

Sosei Heptares

Tempest Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development

Eisai Co Ltd

Eli Lilly and Co

GlaxoSmithKline Plc

Kaken Pharmaceutical Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Tempest Therapeutics Inc

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles

AAT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARTEP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-6086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

grapiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-726701A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAG-308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4578 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMX-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize EP2 and EP4 Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones

Featured News & Press Releases

May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments

Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007

Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China

Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China

Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China

Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress

Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)

Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan

Mar 30, 2017: Treatment of Cancer Use Patent for EP4 antagonist Approved in US

Aug 17, 2016: Treatment of Cancer Use Patent for EP4 antagonist Approved in China

Jun 03, 2016: Autoimmune disease Use Patent for EP4 antagonist Approved in Mexico

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by ARTham Therapeutics Inc, H2 2019

Pipeline by AskAt Inc, H2 2019

Pipeline by Eisai Co Ltd, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by GlaxoSmithKline Plc, H2 2019

Pipeline by Kaken Pharmaceutical Co Ltd, H2 2019

Pipeline by Mesentech Inc, H2 2019

Pipeline by NB Health Laboratory Co Ltd, H2 2019

Pipeline by Ono Pharmaceutical Co Ltd, H2 2019

Pipeline by RaQualia Pharma Inc, H2 2019

Pipeline by Rottapharm Biotech Srl, H2 2019

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019

Pipeline by Sosei Heptares, H2 2019

Pipeline by Tempest Therapeutics Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

Discontinued Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports